# Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

> **NCT02333058** · PHASE2 · COMPLETED · sponsor: **medac GmbH** · enrollment: 70 (actual)

## Conditions studied

- Acute Lymphoblastic Leukaemias (ALL)
- Acute Myeloid Leukaemias (AML)
- Myelodysplastic Syndromes (MDS)
- Juvenile Myelomonocytic Leukaemias (JMML)

## Interventions

- **DRUG:** Treosulfan

## Key facts

- **NCT ID:** NCT02333058
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-21
- **Primary completion:** 2016-12-24
- **Final completion:** 2019-09-30
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333058, "Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02333058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*